Myriad Genetics INC Form 4 insider transactions

Scott J. Leffler, CFO of Myriad Genetics, files an amendment to correct the number of restricted stock units granted on March 14, 2024.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 363 common stock shares to cover tax obligations related to vesting restricted stock units on March 25, 2024.

Pamela Wong, Chief Legal Officer of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units and is no longer subject to Section 16 reporting as of March 22, 2024.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, disposed of 730 shares of common stock on March 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reported disposing of shares to cover tax withholding obligations related to vesting restricted stock units.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Pamela Wong, Chief Legal Officer of Myriad Genetics, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquiring 7,500 shares of common stock as part of a restricted stock unit grant.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.

Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reports acquisition of restricted stock units and disposal of shares to cover tax obligations.

Shereen Solaiman, Chief People Officer at Myriad Genetics, reports the acquisition of 41,042 shares of common stock through a restricted stock unit grant.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition of restricted stock units and subsequent disposal of shares to cover tax obligations.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired shares through restricted stock units and disposed of shares to cover tax obligations.

Chief Operating Officer of Myriad Genetics, Samraat S. Raha, reports acquiring and disposing of common stock and holding 300,854 shares following the transaction.

Chief Financial Officer Scott J. Leffler of Myriad Genetics reported the acquisition of restricted stock units and the disposal of common stock on March 14, 2024.

Paul Diaz, President and CEO of Myriad Genetics, reports acquisition of stock units and disposition of shares to cover tax obligations.

Chief People Officer Shereen Solaiman of Myriad Genetics reports the withholding of shares to cover tax obligations related to vested restricted stock units.